Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed Sales Boosted By Impella Reorders In Fiscal Q4

This article was originally published in The Gray Sheet

Executive Summary

Abiomed sales advanced 17% to $23 million for the most recent fiscal quarter, driven by Impella percutaneous cardiac assist system reorders, despite 68% slower growth in the customer base

You may also be interested in...



Abiomed Impella 5.0

Firm gains 510(k) clearance for its Impella 5.0 and Impella LD minimally invasive catheter-based circulatory support pumps, which provide circulatory support for up to six hours. The pumps are driven by the same console as the Impella 2.5, which was cleared by FDA in June 2008, but provide up to five liters of blood flow per minute instead of 2.5 1("The Gray Sheet" June 9, 2008, p. 20). While the 5.0 version is implanted via the femoral artery (as is the 2.5 model), the LD model is inserted through the chest. The devices can provide a therapeutic benefit from "ventricular unloading," the company explains (2"The Gray Sheet" Nov. 17, 2008, p. 5)

Sun Denied Over US Antitrust Challenge

India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.

Former Sandoz Executive Kellum Admits US Price-Fixing

Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.

Topics

UsernamePublicRestriction

Register

MT028899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel